Objectives. Several aquaporins (AQPs) are present in the salivary glands, likely contributing to their secretions. AQP dysfunction may contribute to the salivary gland dysfunction in SS. Antibodies to AQP4 and AQP1 are detected in neuromyelitis optica and are believed to play a pathogenic role. We aimed to search for antibodies to several AQPs in the sera from SS patients in an effort to shed light on the pathogenic mechanisms of SS.
Introduction
SS is a chronic autoimmune disease affecting exocrine glands, specifically salivary and lacrimal glands [1] . Patients with SS mainly have ocular and oral involvement, which leads to xerostomia and dry eyes; however, other organs may be involved as well [1] .
Antibodies to several antigens are known to be present in most SS patients. Known autoantigens include SSA/Ro and SSB/La; however, these autoantigens are not SS specific [2] and it is yet unknown whether these autoantibodies play any pathogenic role in SS. Nevertheless, strong experimental data point to the direction that in some cases autoantibodies are actively involved in SS [3, 4] . The hallmark of SS is the dysfunction of exocrine glands, which is mainly caused by inflammatory infiltration. However, other mechanisms may be involved as well. In a subset of patients with SS, autoantibodies against acetylcholine receptors may cause dryness by blocking neuroglandular transmission [5, 6] . Moreover, additional autoantibodies have been identified, such as antibodies against NA14, PA28a, salivary gland protein 1, carbonic anhydrase 6, parotid secretory protein and TRIM38 [7] , yet their clinical significance, if any, remains to be determined.
Aquaporins (AQPs), a family of at least 13 water channels (AQP0AQP12) play a vital role in the passage of water and secretions across plasma membranes [8] . Since water movement is necessary for the production of saliva and tears, AQPs may play a central role in SS, and several AQPs have been detected in salivary glands [911] . Furthermore, changes in AQP1 and AQP5 expression have been reported in xerostomic conditions [11, 12] . Interestingly, AQP1 gene therapy restored fluid movement in a murine SS model in which AQP5 was downregulated [13] . Interestingly, adenoviral-mediated transfer of AQP1 cDNA for radiation-induced salivary hypofunction [14] has been shown to alleviate xerostomia in experimental animals and encouraging phase I clinical trials have been published [15] .
Antibodies to AQP4 and AQP1 have been found in the sera of patients with the autoimmune disease neuromyelitis optica (NMO) [16, 17] and the pathogenic role of AQP4 antibodies has been confirmed [18] . Due to the likely vital role of AQPs in the salivary glands, and the involvement of immune mechanisms in SS, the presence of AQP antibodies in SS justifies investigation. AQP5 antibodies were recently detected in SS sera [19] , but no antibodies to other AQPs have been previously detected in SS without concurrent NMO [20] .
We here show a high frequency of antibodies to AQP8 and AQP9 and lower frequency to AQP1 and AQP3 in sera from 34 patients with primary SS (overall 38% AQP antibodypositive), while no such antibodies were detected in any of the 172 control sera. Expression of the most antigenic AQP (AQP8) in human salivary glands was detected by immunohistochemistry. These antibodies bind to the extracellular domains of the corresponding AQPs. Patients with anti-AQP antibodies had significantly more severe xerophthalmia, as objectively assessed, compared with anti-AQP-negative patients, suggesting a potential pathogenic role of these antibodies.
Methods
Patients and serum samples SS patients were recruited from outpatient clinics at the Department of Rheumatology of Patras University Hospital during routine follow-up appointments. Serum samples were obtained following written informed consent and were tested at the Hellenic Pasteur Institute, Athens. An SS diagnosis was based on the AmericanEuropean Consensus Group Classification Criteria [21] . Patients with other concurrent systemic rheumatic diseases were excluded. All patients were ANA positive and had anti-Ro and/or anti-La autoantibodies; moreover, most patients had been subjected to salivary gland biopsy, which was positive in all tested cases (n = 27). Xeropthalmia was objectively assessed by Shirmer test I and Rose Bengal staining (quantified by the Van Bijsterveld method) in all patients. The main characteristics of the 34 patients are shown in Table 1 . Sera from patients with other autoimmune diseases (OADs) included sera from 62 myasthenia gravis patients and from 6 patients with LambertEaton myasthenic syndrome; these sera were collected for diagnostic tests at the Hellenic Pasteur Institute and Tzartos NeuroDiagnostics with the patients' informed consent. Sera from healthy controls (HCs) were donated by personnel of the Hellenic Pasteur Institute and by routine diagnostic laboratories. AQPs and AQP peptides Human AQP3 and AQP9 were from Origene (Rockville, MD, USA) as fusion proteins with C-terminal myc and DYKDDDDK tags (DDK-tag) expressed in HEK293 cells, whereas AQP8 was purchased from Novus Biologicals (Cambridge, UK) as fusion protein with a glutathione-Stransferase tag expressed in the wheat germ cell-free protein expression system and affinity purified on immobilized glutathione. The His-tag AQP1 and AQP4 were expressed and affinity purified as described [17] . Synthetic peptides corresponding to the three extracellular domains of each human AQP and the corresponding scrambled peptides (as controls) were synthesized and high-performance liquid chromatography purified (>80% purity; JPT Peptide Technologies, Berlin, Germany) (supplementary Fig. S1 , available at Rheumatology Online).
ELISA with synthetic peptides and peptide mapping experiments Ninety-six-well plates were coated by overnight incubation at 4 C with a mixture of three peptides corresponding to the extracellular domains of a human AQP (0.2 mg of each peptide), or 0.6 mg BSA as control, in 50 ml 0.01 M carbonate buffer, pH 9.6, per well, washed three times with PBS/0.05% Tween-20 and once with PBS and blocked by incubation for 1 h at room temperature with 4% BSA in PBS. After three washes with PBS/0.05% Tween 20 and one wash with PBS, sera were added at a 1/100 dilution in PBS/2% BSA and the plates incubated overnight at 4 C. After washing as above, horseradish peroxidase (HRP)-conjugated rabbit anti-human IgG antibodies (1/5000 in 2% BSA/PBS) were added and incubated for 1 h at room temperature, washed as above and incubated for 15 min at room temperature with 3,3 0 ,5,5 0 -tetramethylbenzidine. Colour was quantified at 450 nm after stopping the reaction with 0.2 M sulphuric acid. Values were considered positive when they were 550% higher than the mean optical density at 450 nm (OD 450 ) for normal control sera, a value that, using serum samples from 30 HCs, was higher than the mean OD 450 of the controls plus 3 S.D. All measurements were performed at least twice. Background binding (i.e. the OD of HC sera) was similar between different peptides of the different AQPs and albumin; i.e. the peptides did not increase the background above that of albumin and therefore a similar cut-off was used for all peptides. The antibody-positive sera were then tested with individual peptides and with selected scrambled peptides (0.2 mg peptide per well). C with 50 ml of PBS containing 0.5% Triton X-100, pH 7.4 (assay buffer) and 0.1 mg of 125 I-labelled AQP, then 50 ml of goat antihuman Ig was added and the mixture was incubated for 2 h at 25 C and centrifuged; the pellet was washed twice with 1 ml of assay buffer and the radioactivity in the pellet measured in a gamma counter. The binding of commercial sera against AQP1 (Millipore) and AQP8 (OriGene) at $6 nM was also tested. In this case, instead of antihuman IgG, 3 ml of a mixture of sepharose protein-A and protein-G was used. This mixture gave very similar cpm values as those obtained with anti-human Ig. All measurements were performed at least twice. The average value of 33 tests with the different AQPs using healthy donor sera plus 5 S.D. (250 + 5Â32 = 410 cpm) was considered the positive cut-off. It was calculated that 103 Ácpm corresponded to $1 nM anti-AQP antibody. To confirm the antibody specificity, 5 ml of serum was pre-incubated with 0.1 mg of loop peptide, or its corresponding scrambled peptide, for 2 h at room temperature and the assay was continued as described above.
Detection of antibody binding to AQPs by western blotting AQP1 and AQP8 were electrophoresed on a 12.5% SDSpolyacrylamide gel and transferred onto polyvinylidene difluoride (PVDF; 0.25 mg protein per lane) membranes. The membranes were then incubated with the sera (diluted 200Â in 0.2% BSA in PBS) for 1 h at 25 C with 3% BSA in PBS, then for 2 h at 4 C. They were then washed and incubated for 90 min at 4 C with HRP-conjugated anti-human antibody (1:5000 dilution), washed with PBS and incubated with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA) to visualize antibody binding after film exposing in a film cassette according to the manufacturer's procedure. The PVDF membranes were stripped and reprobed with different sera according to the manufacturer's protocol. To further verify the specificity of antibody binding to the peptides, anti-AQP-positive sera were pre-incubated for 2.5 h at 25 C with 0.3 mg of the same protein or with 0.3 mg of individual peptides, including corresponding scrambled peptides, to the equivalent AQP.
Detection of antibody binding to the extracellular regions of cell-embedded AQPs HEK293 cells were transfected with AQP green fluorescent proteins (GFPs). The cells were collected 48 h after transfection, washed twice with PBS and counted. Samples (1.25 ml) of anti-AQP antibody-containing sera were pre-incubated for 2 h at room temperature with intact transfected HEK293 cells in 50 ml of PBS, then the mixtures were centrifuged and the major fraction of their supernatants (corresponding to 1 ml serum) was collected and tested in the ELISA described above, with peptide mixtures corresponding to the individual AQPs, to determine the remaining unbound antibodies. The ratio of the specific OD (i.e. the OD after the deduction of the OD obtained from the HC sera) of the depleted serum by the specific OD obtained by the same serum pre-incubated with plain buffer is interpreted as the fraction of the remaining unbound antibodies.
Immunohistochemistry
Immunohistochemistry was performed on formalin fixed and paraffin-embedded minor salivary glands of the lip from 10 SS patients and 5 HCs. Sections of 4 mm thickness, obtained from tissue blocks, were deparaffinized in xylene and rehydrated in a series of graded ethanol solutions. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15 min. For antigen retrieval, sections were heated in 1 mM EDTA in 10 mM Tris buffer (pH 8.5) for 15 min in a microwave oven (600 W). After cooling to room temperature, sections were incubated with blocking serum (1% BSA Fraction V, Serva Electrophoresis, Germany) for 30 min. Then the sections were incubated for 1 h at room temperature with rabbit antibody against AQP8 (1:100; Origene TA310192 
Results
Detection of antibodies to the extracellular domains of AQPs in sera from SS patients We screened 34 sera from SS patients (Table 1) for binding to the extracellular domains of AQPs 1, 3, 4, 5, 8 and 9, 68 sera from patients with OADs and 106 sera from HCs. Specifically, we performed ELISAs with mixtures of three peptides containing residues corresponding to those of the extracellular loops of each AQP (underlined residues, supplementary Fig. S1 , available at Rheumatology Online). Yet it should be noted that some peptides also contain residues flanking the loop residues; in these cases, serum binding to a peptide suggests binding to the larger region that contains the loop. Fig. 1A shows that two sera bound to the AQP1 peptide mixture, one to AQP3, six to AQP8 and four to AQP9. All sera bound to only one AQP, thus excluding any cross-reactivity. Overall, 38.2% of the 34 sera were antibody positive. In contrast, none of the 68 OAD sera and only 3.8% (4/106) of the HC sera bound to AQPs 1, 3, 8 and 9 ( Fig. 1B and C) .
We also collected serum from an anti-AQP9 patient (no. 22 in Fig. 1A) 12 months later. The new serum remained similarly positive (serum 22a; Fig. 1A ), suggesting that these antibodies persist in time in the positive patients. No major changes in the clinical state of the patient between the two bleedings were observed.
We then screened the positive sera for binding to individual peptides containing the segments corresponding to single extracellular loops. Fig. 1D shows that each positive serum bound only to a single loop (only one anti-AQP8 serum had somewhat elevated antibodies to a second loop). Seven sera bound to A loops, five to E loops and only one bound to a C loop. In contrast, the scrambled peptides (corresponding to most positive peptides) did not bind any serum, confirming the binding specificity of the peptide loops.
Subsequently we tested whether serum binding to the synthetic peptides indeed represents binding to the corresponding intact AQPs. We performed RIAs with indirectly 125 I-labelled AQPs. All SS and selected HC sera were tested with 125 I-labelled AQPs 1, 8 and 9. Fig. 2 shows that the ELISA and RIA results agreed very well: all peptide-positive SS sera also bound similarly to the corresponding intact AQPs, with antibody titres of 2.010 nM. In contrast, only one ELISA-negative SS serum was RIA positive (SS24); its antibodies may be either specific for the cytoplasmic side of AQP8 or specific for conformational epitopes. Interestingly, the two HC sera, which were the only ones positive for the AQP8 peptide mixture out of the 106 HC sera (Fig. 1C) , were RIA negative with the intact AQP8. Nine additional HC sera were also tested with the 125 I-labelled AQPs and were found to be negative. In addition, we tested the single AQP3 peptidepositive serum (SS4) and 5 HC sera, including the two sera that were ELISA positive for AQP3 peptides (Fig. 1C) . Interestingly, serum SS4 was also found to be RIA positive, whereas all HC sera, including the two ELISA-positive sera, were RIA negative (data not shown).
We then tested whether the antipeptide antibodies constitute a minor or major fraction of the total anti-AQP antibodies. Supplementary Fig. S2 , available at Rheumatology Online, shows that pre-incubation of the sera with their specific peptide loop totally inhibited antibody binding to 125 I-AQP, whereas practically no inhibition was observed with the corresponding scrambled peptides. This shows that practically all AQP antibodies for each tested serum bind to a single loop and their epitopes are sequential.
The above results were further confirmed by western blotting with anti-AQP1-and anti-AQP8-positive sera. Fig. 3 presents the results with the PVDF membranes: all AQP8 antibodycontaining sera tested bound to www.rheumatology.oxfordjournals.org AQP8 but not to AQP1, and similarly the AQP1 antibodycontaining sera bound only to AQP1. In addition, sera from AQP-negative SS patients did not bind to either AQP. A further confirmation of the loop specificity of the antibodies is shown in supplementary Fig. S3 , available at Rheumatology Online, where pre-incubation of four AQP8-positive SS sera with their specific peptide (but not with the scrambled peptides or with irrelevant loop peptides) showed complete inhibition of binding.
Finally, we examined whether the anti-AQP antibodies could bind to intact HEK293 cells expressing recombinant AQPs. Initially we tried to develop cell-based assays with HEK293 cells transfected with AQP1-GFP, AQP3-GFP and AQP8-GFP but, apparently due to their very low surface expression (as suggested from the following experiments), we did not achieve positive results (data not shown). Thus we then applied an alternative approach we had developed earlier that is appropriate also for low surface expression of the target molecule [17] . This involved a combined immunoadsorption with ELISA experiment in which the test sera were pre-incubated with intact AQP-GFP transfected or untransfected HEK293 cells or with plain buffer, followed by ELISA on the depleted sera. As shown in Table 2 , 1 000 000 AQP1 transfected cells were needed for complete immunoadsorption of the anti-AQP1 antibodies, while 300 000 AQP1 transfected cells adsorbed $3343% of the antibodies from 1.25 ml of serum. The 1 000 000 AQP8 transfected cells were less efficient, depleting only 48 and 13% of the corresponding antibodies from the two tested AQP8 sera. Smaller cell numbers were not efficient (data not shown). In contrast, near complete removal of the AQP4 antibodies from 1.25 ml NMO serum was achieved by only 10 00015 000 AQP4 transfected cells (data not shown).
AQP8 expression in human salivary glands
The presence of anti-AQP8 antibodies was the most common finding in the tested SS sera. We thus studied the immunohistochemical expression of AQP8 (by a commercial anti-AQP8 antibody) in minor salivary glands from 10 SS patients (3 with and 7 without AQP8 antibodies) and 5 healthy individuals. AQP8 was detected in the salivary glands of all tested samples, mostly localized in the cytoplasm of excretory ducts (Figs 4A and B) . Intense staining was observed in 2/3 (66%) of the biopsies from SS patients with anti-AQP8 antibodies but only in 3/7 (43%) from SS patients without anti-AQP8 antibodies and 2/4 (50%) healthy individuals. Yet the very small numbers of biopsies studied cannot ensure the significance of the difference. The acinar cells showed less AQP8 expression or were totally negative ( Figs 4A and B) .
Clinical characteristics of the patients with AQP antibodies
We searched for any differences between patients positive and negative for AQP antibodies. All patients with AQP antibodies were grouped together because their number was relatively small (n = 13). We first explored potential associations between the presence of anti-AQP antibodies and xeropthalmia as objectively assessed by Shirmer test and Rose Bengal staining. The percentage of patients with a Shirmer test <5 mm did not differ between the two groups (76.9 vs 71.4% for positive and negative patients, respectively; P = ns). However, the Van Bijsterveld score was significantly higher in anti-AQPpositive compared with negative patients [median 4 (IQR 45) vs 3 (34) for positive and negative patients, respectively; P = 0.037]. These data point to the direction that anti-AQP antibodies may associate with the severity of xeropthalmia, thus supporting the view that these antibodies may be pathogenetically involved.
We did not find any differences in clinical characteristics and treatments between the AQP-positive and negative subgroups (Table 1) . We further looked for any differences in extra-epithelial manifestations (such as arthritis, skin vasculitis, interstitial lung disease) by thoroughly reviewing the patients' medical records; similarly, no differences were found between the two patient groups. We assessed whether the presence of a specific AQP antibody associated with a specific clinical pattern, but we found no correlation. Furthermore, since salivary gland biopsies were available in most patients (n = 27), we assessed whether the presence of anti-AQP antibodies was associated with the intensity of lymphocytic infiltration. We did not find any differences between AQP-positive and negative patients. The median focus score was 1 (IQR 12.25) vs 1 (11.5) for the AQP-positive and AQP-negative patients, respectively (P = ns).
Discussion
SS is thought to be an autoimmune disease. However, the pathogenicity of the known autoantigens is not yet proven and some patients are seronegative. Here we studied SS sera for the presence of antibodies to AQPs, which are important for water movement across cells and seem to play an important role in salivary gland secretions. Expression of AQPs 1, 3, 4, 5, 8, 9 and 11 in salivary glands has been detected, with AQP5 as only AQP thus far clearly shown to play a major role in the salivary secretion process [911] . Modifications in AQP expression and/or distribution have been reported in xerostomic conditions [12] .
In our previous studies on the detection of AQP1 antibodies in sera from NMO spectrum disorders or multiple sclerosis patients, we saw that practically all sera binding to the intact AQP1 also bound to some of the synthetic peptides corresponding to its extracellular or cytoplasmic segments [17] . As expected, sera with antibodies to extracellular epitopes were better related to NMO disease [17] . Therefore, in the present study we chose to initially screen the sera with the peptides corresponding to the extracellular AQP C for 30 min) were electrophoresed and transferred onto PVDF membranes, which were then incubated with the test sera (anti-AQP1, anti-AQP8 or commercial anti-AQP antibodies, as shown). It can be seen that anti-AQP specificity of the sera previously determined by ELISA and RIA completely agrees with the Western blot experiments. Serum samples were pre-incubated with the specified numbers of AQP transfected or untransfected cells or with plain buffer (for the 100% binding). The supernatants were tested in an ELISA with the mixture of the three extracellular peptides of AQP1 or AQP8.
domains. The positive sera were then tested for binding to the intact AQPs with RIA and western blot analysis. Finally, although we could not develop cell-based assays for these AQPs, apparently because of their too low surface expression in HEK293 cells, by an alternative approach involving a combined immunoadsorption with ELISA experiment we showed that all AQP1 antibodies and at least part of the AQP8 antibodies are capable of binding on the extracellular side of the cell-embedded corresponding AQPs.
We found that 38.2% of the tested sera from primary SS patients had antibodies to extracellular AQP epitopes. Although it is unlikely that the peptides acquired the conformation of the corresponding domains in the intact molecules, interestingly all peptide-positive SS sera also bound to the corresponding intact AQPs. Most were against AQP8 (6/34) and AQP9 (4/34) and fewer against AQP1 (2/34) and AQP3 (1/34); no serum had antibodies to AQP4 or AQP5, despite the known significance of AQP5 in salivary gland function and the recent detection of AQP5 antibodies by another group [19] . Judging from a single AQP9 antibodypositive patient for whom we tested sera with a 1 year interval, the presence of AQP antibodies may be persistent in time. All four antigenic AQPs have been found previously in mammalian salivary glands and we found here that at least the most antigenic of them, AQP8, is also present in human salivary glands (Fig. 4) .
Each positive serum bound only to one AQP, suggesting no cross-reactivity between them, and to only a single peptide containing the residues of one extracellular loop. Yet all three extracellular loops were antigenic for some sera. All SS sera positive for any AQP peptide(s) were then tested for binding to the intact AQPs and all were found positive for the corresponding AQPs (Fig. 2) . Western blot analysis visualized the AQP binding and further confirmed its specificity. Interestingly, competition experiments between synthetic peptides and intact AQPs showed that practically all anti-AQP antibodies could bind to the synthetic peptides (supplementary Fig. S2 and 3 , available at Rheumatology Online), i.e. their binding is not conformation dependent.
The specificity of binding was also supported by the observation that even the rare (4/106) HC sera that bound to AQP peptides did not bind to the corresponding intact AQPs (Fig. 2) ; therefore their binding to AQP peptides seems non-specific. This suggests that although binding to AQP peptides is usually sufficient, confirmation of the specificity requires the complementary use of an assay with intact AQP. Furthermore, none of the 68 OAD sera bound to any AQP or peptide.
In conclusion, we found that a significant percentage of patients with SS have autoantibodies against four AQPs, molecules with possible function in the salivary glands. The fact that the presence of anti-AQP antibodies significantly correlated with the severity of xeropthalmia supports the view that these antibodies may have a functional effect. Yet whether these antibodies play any role in SS or are a bystander effect remains to be determined in future studies.
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